Skip to main content
Fig. 2 | Molecular Neurodegeneration

Fig. 2

From: A brain-targeted, modified neurosin (kallikrein-6) reduces α-synuclein accumulation in a mouse model of multiple system atrophy

Fig. 2

Neurosin distribution in the brain following systemic administration of LV-Neurosin-apoB vector into MBP-α-syn tg mice. Non-tg and MBP-α-syn tg mice received a single intra-peritoneal injection of LV-Control or LV-NR-R80Q-apoB (1 × 109 TDU). Three months later mice were sacrificed, whole blood, CSF and brains were removed with half frozen for protein analysis and half fixed for tissue section immunohistochemistry. a Representative immunoblot from brain homogenates that were fractioned into soluble and insoluble fractions by ultracentrifugation and analyzed with antibodies for neurosin and the epitope tag, V5. Neurosin was detected as a double band at approximately 28 kDa. b, c Densitometry analysis of the levels of neurosin and V5 immunoreactivity plotted against the actin signal. d Hemibrains were serially sectioned on the longitudinal axis and immunostained with an antibody against neurosin. e Semiquantitative analysis of levels of neurosin immunostaining in the striatum expressed as optical density. f Representative immunoblot analysis of neurosin in plasma portion of the blood and in whole CSF. (g, h) Densitometry analysis of neurosin in the blood and CSF. n = 10 mice per group 9–10 m/o at the end of the treatment. * - indicates one way ANOVA with post hoc Dunnett’s, p < 0.05 compared to non-tg mice that received LV-Control. # - indicates one way ANOVA with post hoc Tukey-Krammer, p < 0.05 compared to MBP-α-syn tg mice that received LV-Control. Scale bars = Overview 200 μm, Striatum 40 μm

Back to article page